BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31292797)

  • 1. Lynch syndrome with exclusive skin involvement: time to consider a molecular definition?
    Vaisfeld A; Calicchia M; Pomponi MG; Lucci-Cordisco E; Reggiani-Bonetti L; Genuardi M
    Fam Cancer; 2019 Oct; 18(4):421-427. PubMed ID: 31292797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
    Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
    J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Muir-Torre syndrome and Turcot syndrome].
    Velter C; Caussade P; Fricker JP; Cribier B
    Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
    Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
    Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome.
    Georgeson P; Walsh MD; Clendenning M; Daneshvar S; Pope BJ; Mahmood K; Joo JE; Jayasekara H; Jenkins MA; Winship IM; Buchanan DD
    Mol Genet Genomic Med; 2019 Jul; 7(7):e00781. PubMed ID: 31162827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
    Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
    J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and molecular characteristics of DNA mismatch repair protein-deficient sebaceous neoplasms and keratoacanthomas in a Japanese hospital-based population.
    Kuwabara K; Suzuki O; Chika N; Kumamoto K; Minabe T; Fukuda T; Arai E; Tamaru JI; Akagi K; Eguchi H; Okazaki Y; Ishida H
    Jpn J Clin Oncol; 2018 Jun; 48(6):514-521. PubMed ID: 29718441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.
    Rajan Kd A; Burris C; Iliff N; Grant M; Eshleman JR; Eberhart CG
    Am J Ophthalmol; 2014 Mar; 157(3):640-7.e1-2. PubMed ID: 24321472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
    Jessup CJ; Redston M; Tilton E; Reimann JD
    Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
    Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
    Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer.
    Cesinaro AM; Ubiali A; Sighinolfi P; Trentini GP; Gentili F; Facchetti F
    Am J Dermatopathol; 2007 Aug; 29(4):351-8. PubMed ID: 17667167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
    Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
    Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
    Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
    Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinico-pathological predictors of mismatch repair deficiency in sebaceous neoplasia: A large case series from a single Australian private pathology service.
    Walsh MD; Jayasekara H; Huang A; Winship IM; Buchanan DD
    Australas J Dermatol; 2019 May; 60(2):126-133. PubMed ID: 30506759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome.
    Cruz-Correa M; Diaz-Algorri Y; Pérez-Mayoral J; Suleiman-Suleiman W; Gonzalez-Pons Mdel M; Bertrán C; Casellas N; Rodríguez N; Pardo S; Rivera K; Mosquera R; Rodriguez-Quilichini S
    Fam Cancer; 2015 Sep; 14(3):415-25. PubMed ID: 25782445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
    Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
    Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.
    Neelakantan IV; Di Palma S; Smith CE; McCoombe A
    Head Neck Pathol; 2016 Sep; 10(3):354-61. PubMed ID: 26577210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC.
    Ollila S; Fitzpatrick R; Sarantaus L; Kariola R; Ambus I; Velsher L; Hsieh E; Andersen MK; Raevaara TE; Gerdes AM; Mangold E; Peltomäki P; Lynch HT; Nyström M
    Int J Oncol; 2006 Jan; 28(1):149-53. PubMed ID: 16327991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome.
    Lamba AR; Moore AY; Moore T; Rhees J; Arnold MA; Boland CR
    Fam Cancer; 2015 Jun; 14(2):259-64. PubMed ID: 25637498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.